EXECUTIVE FORUM

April 18, 2026 (10 AM – 5 PM)

Chinese American Chemical Society (E-CACS), Asian American Entrepreneur Association (AAEA) and Fox Rothschild cordially invite you to an exclusive discussion on preclinical strategies, FDA regulations, and technology transfer & licensing.

I. Preclinical strategies

- Smarter DMPK to De-Risk Early Programs
- Translational Pharmacology and Biomarker Strategy
- Selection and Justification of Translational Models
- Front-Loading Developability and CMC Considerations
- Regulatory-Informed Preclinical Planning
- DMPK strategies for CNS Models and Biomarkers

Expert Panel

- Marla Weetall, PTC Therapeutics
- Aidan Smith, WuXi AppTec
- Dong Liu, Seed Therapeutics

II. Compliance & Regulations

- Navigating Regulatory and Compliance Challenges
- Preclinical Study Design Under Increasing Emphasis on Translational Relevance
- Preclinical Implications of FDA's Push Toward Faster Drug Approvals
- AI and Advanced Analytics in FDA Filing and Review

Expert Panel

- Qi Cheng, Takeda Pharmaceuticals
- Ran He, THC Lawyers
- Andrew Jiang, Aleon Pharma

III. Technology Transfer & Licensing

- Key Considerations in Technology Transfer
- Valuation and Negotiation Strategies for Licensing Deals
- Due Diligence in Technology Transactions
- Emerging Trends in Life Sciences Licensing
- Key Points in Commercialization strategies

Expert Panel

- Peter Butch, Fox Rothschild
- Jan Jiang, Auson Pharma
- Jasmine Lu, MSQ Ventures
- Shawn Wang, WuXi XDC
- Willie Wu, Breakthrough Genomics

Scan QR code here to register

Address: 101 Carnegie Center Drive, Princeton, NJ 08540